Addendum
Nivolumab (oesophageal or gastro-oesophageal junction cancer, adjuvant) – Addendum to Project A25-88
Report documents
-
Addendum
Nivolumab (oesophageal or gastro-oesophageal junction cancer, adjuvant) – Addendum to Project A25-88
Dossier assessment
Indication:
Adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-12-18 A G-BA decision was published.
Project details
- Project no.
- A25-142
- Commission
- Commission awarded on 12.11.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-142_en
Connected Projects
-
Dossier assessment
Nivolumab (oesophageal or gastro-oesophageal junction cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (urothelial carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed